Trials / Completed
CompletedNCT03418168
A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects
An Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Peritoneal Dialysis Subjects With Renal Anemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of molidustat in peritoneal dialysis subjects with renal anemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Molidustat (BAY85-3934) | Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response |
Timeline
- Start date
- 2018-02-22
- Primary completion
- 2019-07-25
- Completion
- 2019-07-29
- First posted
- 2018-02-01
- Last updated
- 2021-01-29
Locations
27 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03418168. Inclusion in this directory is not an endorsement.